• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173059 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ' X2 o# m% \7 \* Z1 R

8 k! [# c3 m3 Q  X; ^# t
) V* w: }- W* w* x7 _" d1 wSub-category:- R- X6 \' O" l5 r
Molecular Targets
( h+ V! H9 E# h0 j; b  G, q  ]% A: N' V! u/ G2 ^1 c" A
, ]( [) m* F$ N% {, ^0 m" p
Category:
8 B1 _$ @5 A* a8 l: x2 \  WTumor Biology
. r8 u9 c) U' T4 m1 G
& [4 u' y: C# c# X) @) _  f3 Z' f& N. w0 p- T6 E; Z2 ?8 }
Meeting:
' N! N  F, K9 L2 k, S" c! R2011 ASCO Annual Meeting ) |8 r" K' h; C6 t& ]7 `" `9 j
6 [& D, e8 s: W4 `9 l' ?# a
3 U; `4 k, N! {$ d% @3 C
Session Type and Session Title:
5 [6 J0 B5 g# A! w4 q% APoster Discussion Session, Tumor Biology
, ~  [* \" P! A" U! Q/ S
4 b( e( |0 B1 B4 X1 _5 l# D. q( T- E% `/ e. Q5 @6 f# @
Abstract No:0 c* O; A+ ~6 Q% \5 X
10517 " n/ [( Y& I4 Z1 i$ W* y# O4 x
5 @: u2 v# S" n8 s( B. D% n
' u# G# R  z6 K6 P/ H7 L
Citation:3 @' D; I% t: D0 H# O
J Clin Oncol 29: 2011 (suppl; abstr 10517) / l& o8 J6 D; e$ O. l; D
  w+ y/ G% ^( r0 O1 d

) s# t2 Y  u) J) ^Author(s):. j( e6 ]3 [, k$ o0 Q5 y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 _, h4 m5 k0 w( i
' I" k$ d! E+ m8 k- v: i8 u
0 W2 |+ y9 W) K! {8 S" M: S- a/ O  S8 j9 `4 j1 n  M/ ^5 B
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 y) ^2 M& r7 C$ S% l. R2 G4 P0 h4 B
% S6 W! M6 a; c# {& Q6 G
Abstract Disclosures
( v* z7 B9 ^/ d" C8 _7 p  R9 g0 l& z8 ^
Abstract:
' h2 N9 X/ U$ P1 z. N& l' F8 Y1 |) i, \. l4 U' [- l
$ S* s9 a( {, k5 l; @
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.3 ]+ _  h& G- R! R! u4 }9 r# ?1 J

, [# x. ~0 Q1 t: A$ ^& A( r: J
# f9 s0 y* B9 _) z2 b! E
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
6 U* j7 ~# [; e3 z没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

3 {3 Z2 V# n# S' |+ W# @* T化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20   o, D/ e5 G. [1 y5 e
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
) i: j" r& }" W  g, lALK一个指标医院要900多 ...
) O, M) N/ J$ S5 i/ `9 f
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?' o  W' a  o7 t' g2 D) u/ t
7 [; K2 S" j/ o
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表